manilatimes

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement ...

SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
Seeking Alpha

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

East Hanover, N.J., Aug. 7, 2024 /PRNewswire/ -- Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class ...
Zonebourse

First Class Metals signe un accord avec Nuinsco pour un complément de prix à Zigzag

(Alliance News) - First Class Metals PLC a déclaré jeudi avoir signé un accord avec Nuinisco Resources Ltd, complétant ainsi le processus d'un accord d'exclusivité décrit en décembre. La société de ...
Yahoo Finance

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a first-in-class complement inhibitor for the reduction of ...
Yahoo Finance

Achillion Begins Study on First Complement Factor D Inhibitor

Achillion Pharmaceuticals, Inc. ACHN announced that it has started a phase I study on its first orally administered small molecule complement factor D inhibitor, ACH-4471. The randomized, ...
Mena FN

Myasthenia Gravis Landscape: Regeneron's NIMBLE Trial Success With Cemdisiran, First Complement C5 Sirna Therapy Delveinsight's Perspective On Market, Competitive Landscape An…

"Myasthenia Gravis Market Insight, Epidemiology and Market Forecast report"DelveInsight's latest analysis highlights the transformative potential of Regeneron Pharmaceuticals' positive Phase 3 NIMBLE ...
Yahoo Finance

FABHALTA Set to Disrupt Complement Inhibitor Market with Oral Convenience and Strong Efficacy | DelveInsight

Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this point ...
Nasdaq

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Company to Present Pipeline Updates at 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 a.m. PT BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ...